Alteon (ALT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT)

ALT 5.390

+16.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jonathan Rothschild who wrote (193)	12/10/1997 10:38:00 AM
From: Rudy Saucillo	Read Replies (1) of 318

Counterfeiters??? That simply should not be a concern when developing sales projections for Pimagedine. No one but ALTN/GNE will have the regulatory approval or legal authority to sell Pimagedine (i.e., assuming the ongoing trials are successful). Yes, other companies are researching AGE formation inhibitors which are structurally different than Pimagedine. I can post more info on these if anyone is interested. All of these are in the early pre-clinical stage and none are competitive with ALTN's. Alteon's second generation program is significantly ahead of these other efforts. I'm not implying there's no competition for marketshare. There's much work ongoing in the areas of diabetic complications and metabolic control. But diabetes is a very complex disease and (short of transplantation for Type I disease) there's no one-therapy cure. Because of the broad systemic effects of Pimagedine, I believe Pimagedine will become a major component in future multi-drug approaches in diabetes treatment. Rudy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next